These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20231393)

  • 1. Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
    Goren MG; Navon-Venezia S; Chmelnitsky I; Carmeli Y
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2687-91. PubMed ID: 20231393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of clonally related Klebsiella pneumoniae isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden.
    Samuelsen Ø; Naseer U; Tofteland S; Skutlaberg DH; Onken A; Hjetland R; Sundsfjord A; Giske CG
    J Antimicrob Chemother; 2009 Apr; 63(4):654-8. PubMed ID: 19218573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway.
    Naseer U; Haldorsen B; Simonsen GS; Sundsfjord A
    Clin Microbiol Infect; 2010 Feb; 16(2):171-8. PubMed ID: 19548922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of Escherichia coli sequence type 410 (ST410) with KPC-2 β-lactamase.
    Mavroidi A; Miriagou V; Malli E; Stefos A; Dalekos GN; Tzouvelekis LS; Petinaki E
    Int J Antimicrob Agents; 2012 Mar; 39(3):247-50. PubMed ID: 22226650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter study of the clonal structure and resistance mechanism of KPC-producing Escherichia coli isolates in Israel.
    Adler A; Miller-Roll T; Assous MV; Geffen Y; Paikin S; Schwartz D; Weiner-Well Y; Hussein K; Cohen R; Carmeli Y
    Clin Microbiol Infect; 2015 Mar; 21(3):230-5. PubMed ID: 25658543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain.
    Leavitt A; Chmelnitsky I; Ofek I; Carmeli Y; Navon-Venezia S
    J Antimicrob Chemother; 2010 Feb; 65(2):243-8. PubMed ID: 19939824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel.
    Navon-Venezia S; Chmelnitsky I; Leavitt A; Schwaber MJ; Schwartz D; Carmeli Y
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3098-101. PubMed ID: 16940107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of a multiresistant KPC-3 and VIM-1 carbapenemase-producing Escherichia coli strain in Spain.
    Porres-Osante N; Azcona-Gutiérrez JM; Rojo-Bezares B; Undabeitia E; Torres C; Sáenz Y
    J Antimicrob Chemother; 2014 Jul; 69(7):1792-5. PubMed ID: 24583362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
    Leavitt A; Navon-Venezia S; Chmelnitsky I; Schwaber MJ; Carmeli Y
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3026-9. PubMed ID: 17562800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTX-M-15-producing multidrug-resistant enteroaggregative Escherichia coli in the United Arab Emirates.
    Sonnevend A; Al Dhaheri K; Mag T; Herpay M; Kolodziejek J; Nowotny N; Usmani A; Sheikh FA; Pál T
    Clin Microbiol Infect; 2006 Jun; 12(6):582-5. PubMed ID: 16700710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases.
    Baroud M; Dandache I; Araj GF; Wakim R; Kanj S; Kanafani Z; Khairallah M; Sabra A; Shehab M; Dbaibo G; Matar GM
    Int J Antimicrob Agents; 2013 Jan; 41(1):75-9. PubMed ID: 23142087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of carbapenem resistance and the first identification of Klebsiella pneumoniae carbapenemase (KPC) enzyme among Escherichia coli isolates in Turkey: A prospective study.
    Kuskucu MA; Karakullukcu A; Ailiken M; Otlu B; Mete B; Aygun G
    Travel Med Infect Dis; 2016; 14(6):572-576. PubMed ID: 27890667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integron-mediated ESBL resistance in rare serotypes of Escherichia coli causing infections in an elderly population of Israel.
    Sompolinsky D; Nitzan Y; Tetry S; Wolk M; Vulikh I; Kerrn MB; Sandvang D; Hershkovits G; Katcoff DJ
    J Antimicrob Chemother; 2005 Jan; 55(1):119-22. PubMed ID: 15574469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway.
    Naseer U; Haldorsen B; Tofteland S; Hegstad K; Scheutz F; Simonsen GS; Sundsfjord A;
    APMIS; 2009 Jul; 117(7):526-36. PubMed ID: 19594493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.
    Simner PJ; Zhanel GG; Pitout J; Tailor F; McCracken M; Mulvey MR; Lagacé-Wiens PR; Adam HJ; Hoban DJ;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):326-34. PubMed ID: 21353961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of plasmid-mediated multidrug resistance in Escherichia coli and Klebsiella oxytoca isolates from clinical specimens in Japan.
    Ode T; Saito R; Kumita W; Sato K; Okugawa S; Moriya K; Koike K; Okamura N
    Int J Antimicrob Agents; 2009 Oct; 34(4):347-50. PubMed ID: 19560903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals.
    Peirano G; Costello M; Pitout JD
    Int J Antimicrob Agents; 2010 Jul; 36(1):19-23. PubMed ID: 20359869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC.
    Haldorsen B; Aasnaes B; Dahl KH; Hanssen AM; Simonsen GS; Walsh TR; Sundsfjord A; Lundblad EW
    J Antimicrob Chemother; 2008 Oct; 62(4):694-702. PubMed ID: 18583329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hidden Carbapenem Resistance in OXA-48 and Extended-Spectrum β-Lactamase-Positive
    Tomić Paradžik M; Drenjančević D; Presečki-Stanko A; Kopić J; Talapko J; Zarfel G; Bedenić B
    Microb Drug Resist; 2019 Jun; 25(5):696-702. PubMed ID: 30614759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan.
    Matsumura Y; Yamamoto M; Higuchi T; Komori T; Tsuboi F; Hayashi A; Sugimoto Y; Hotta G; Matsushima A; Nagao M; Takakura S; Ichiyama S
    Int J Antimicrob Agents; 2012 Aug; 40(2):158-62. PubMed ID: 22743014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.